GERON CORP Equity Securities, FV-NI, Unrealized Gain (Loss)
GERON CORP (GERN) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $60.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-16.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2023-03-16
- GERON CORP equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2020-12-31 was -$49.00K.
- GERON CORP equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2020-09-30 was -$118.00K.
- GERON CORP equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2020-06-30 was $422.00K.
- GERON CORP equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2020-03-31 was -$195.00K, a 298.98% decline year-over-year.
- GERON CORP equity securities, fv-ni, unrealized gain (loss) for fiscal 2020 was $60.00K.
- GERON CORP equity securities, fv-ni, unrealized gain (loss) for fiscal 2019 was -$195.00K.
- GERON CORP equity securities, fv-ni, unrealized gain (loss) for fiscal 2018 was -$541.00K.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$167.00K derived: sum of 2 quarters · filed 2023-03-16 | $255.00K derived: sum of 3 quarters · filed 2023-03-16 | $60.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | -$118.00K 10-Q · filed 2021-11-09 | $304.00K derived: sum of 2 quarters · filed 2021-11-09 | $109.00K 10-Q · filed 2021-11-09 | $109.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $422.00K 10-Q · filed 2021-08-16 | $227.00K 10-Q · filed 2021-08-16 | $227.00K derived: sum of 3 quarters · filed 2022-03-10 | $32.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | -$195.00K 10-Q · filed 2021-05-10 | -$195.00K derived: sum of 2 quarters · filed 2022-03-10 | -$390.00K derived: sum of 3 quarters · filed 2022-03-10 | -$488.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$195.00K derived: sum of 2 quarters · filed 2022-03-10 | -$293.00K derived: sum of 3 quarters · filed 2022-03-10 | -$195.00K 10-K · filed 2022-03-10 |
| 2019-09-30 | -$195.00K 10-Q · filed 2020-11-05 | -$293.00K derived: sum of 2 quarters · filed 2020-11-05 | -$195.00K 10-Q · filed 2020-11-05 | -$466.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | -$98.00K 10-Q · filed 2020-08-06 | $0.00 derived: sum of 2 quarters · filed 2020-08-06 | -$271.00K derived: sum of 3 quarters · filed 2021-03-11 | -$66.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $98.00K 10-Q · filed 2020-05-28 | -$173.00K derived: sum of 2 quarters · filed 2021-03-11 | $32.00K derived: sum of 3 quarters · filed 2021-03-11 | -$318.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | -$271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$66.00K derived: sum of 2 quarters · filed 2021-03-11 | -$416.00K derived: sum of 3 quarters · filed 2021-03-11 | -$541.00K 10-K · filed 2021-03-11 |
| 2018-09-30 | $205.00K 10-Q · filed 2019-11-06 | -$145.00K derived: sum of 2 quarters · filed 2019-11-06 | -$270.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | -$350.00K 10-Q · filed 2019-08-01 | -$475.00K 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | -$125.00K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |